ASPAVELI

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Poland, Romania, Spain.

Active ingredients

The drug ASPAVELI contains one active pharmaceutical ingredient (API):

1	Pegcetacoplan UNII TO3JYR3BOU - PEGCETACOPLAN
	Pegcetacoplan is a symmetrical molecule comprised of two identical pentadecapeptides covalently bound to the ends of a linear 40-kDa PEG molecule. The peptide moieties bind to complement C3 and exert a broad inhibition of the complement cascade. Pegcetacoplan binds to complement protein C3 and its activation fragment C3b with high affinity, thereby regulating the cleavage of C3 and the generation of downstream effectors of complement activation. In PNH, extravascular haemolysis (EVH) is facilitated by C3b opsonisation while intravascular haemolysis (IVH) is mediated by the downstream membrane attack complex (MAC).
	Read more about Pegcetacoplan

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ASPAVELI Solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AJ03		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1871951, 1871962
ES	Centro de información online de medicamentos de la AEMPS	1211595001
FR	Base de données publique des médicaments	67568483
IT	Agenzia del Farmaco	049750019, 049750021
LT	Valstybinė vaistų kontrolės tarnyba	1093846, 1093847
PL	Rejestru Produktów Leczniczych	100463504
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W68382001, W68382002